Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients
James R. Hocker(University of Oklahoma Health Sciences Center), Subrato Deb(Williams (United States)), Min Li(University of Oklahoma Health Sciences Center), Megan R. Lerner(Department of Veterans Affairs), Stan Lightfoot(Veterans Health Administration), Aurelien A. Quillet(University of Oklahoma Health Sciences Center), Rushie J. Hanas(University of Oklahoma Health Sciences Center), Matthew Reinersman(Williams (United States)), Jess L. Thompson(Williams (United States)), Nicole Vu(Analytical Biosciences (China)), Thomas C Kupiec(Analytical Biosciences (China)), Daniel J. Brackett(Veterans Health Administration), Marvin D. Peyton(Williams (United States)), S. Dubinett(University of California, Los Angeles), Harold M. Burkhart(Williams (United States)), Russell G. Postier(Williams (United States)), Jay S. Hanas(Department of Veterans Affairs)
Cited by 19
Abstract
A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.
Related Papers
No related papers found
Powered by citation graph analysis